Breaking News

Astellas, Evopoint Biosciences Enter Exclusive ADC License Agreement 

Astellas gains worldwide rights to develop XNW2701 being evaluated in solid tumors, including gastric, gastroesophageal and pancreatic cancers.

Astellas Pharma and Evopoint Biosciences entered an exclusive license agreement for XNW27011, an investigational clinical-stage antibody-drug conjugate (ADC) targeting CLDN18.2. Astellas gains worldwide exclusive license to develop and commercialize XNW27011 (excluding China’s mainland, Hong Kong, Macao and Taiwan region). Evopoint will receive a $130 million upfront and is eligible to receive up to $70 million near-term payments, and additional milestones associated with development, r...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters